Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines

Anthony N. Karnezis, Shary Yuting Chen, Christine Chow, Winnie Yang, William P.D. Hendricks, Pilar Ramos, Natalia Briones, Anne Marie Mes-Masson, Tjalling Bosse, C. Blake Gilks, Jeffrey M. Trent, Bernard Weissman, David G. Huntsman, Yemin Wang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objective: The development of effective cancer treatments depends on the availability of cell lines that faithfully recapitulate the cancer in question. This study definitively re-assigns the histologic identities of two ovarian cancer cell lines, COV434 (originally described as a granulosa cell tumour) and TOV-112D (originally described as grade 3 endometrioid carcinoma), both of which were recently suggested to represent small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), based on their shared gene expression profiles and sensitivity to EZH2 inhibitors. Methods: For COV434 and TOV-112D, we re-reviewed the original pathology slides and obtained clinical follow-up on the patients, when available, and performed immunohistochemistry for SMARCA4, SMARCA2 and additional diagnostic markers on the original formalin-fixed, paraffin-embedded (FFPE) clinical material, when available. For COV434, we further performed whole exome sequencing and validated SMARCA4 mutations by Sanger sequencing. We studied the growth of the cell lines at baseline and upon re-expression of SMARCA4 in vitro for both cell lines and evaluated the serum calcium levels in vivo upon injection into immunodeficient mice for COV434 cells. Results: The available morphological, immunohistochemical, genetic, and clinical features indicate COV434 is derived from SCCOHT, and TOV-112D is a dedifferentiated carcinoma. Transplantation of COV434 into mice leads to increased serum calcium level. Re-expression of SMARCA4 in either COV434 and TOV-112D cells suppressed their growth dramatically. Conclusions: COV434 represents a bona fide SCCOHT cell line. TOV-112D is a dedifferentiated ovarian carcinoma cell line.

Original languageEnglish (US)
Pages (from-to)568-578
Number of pages11
JournalGynecologic Oncology
Issue number2
StatePublished - Feb 2021


  • COV434
  • Dedifferentiated carcinoma
  • Granulosa cell tumour
  • TOV-112D

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines'. Together they form a unique fingerprint.

Cite this